CD70 and neoplasm: Though a certain drawback of ligand-receptor CARs is the lack of tumor restrictive ligand expression, there remains increased risks of on-target off-tumor toxicity, as shown with CARs targeting CD70 using the costimulatory receptor CD27 (127, 128).